CTI BioPharma ^Partner

CTI BioPharma Corp is a biopharmaceutical company based in Seattle, Washington, focused on developing and commercializing targeted therapies for blood-related cancers. Founded in 1991 and originally named Cell Therapeutics, Inc., the company rebranded in 2014 and became a commercial-stage entity specializing in rare blood cancers. In June 2023, CTI BioPharma was acquired by Swedish Orphan Biovitrum AB (Sobi) and now operates as a subsidiary.

The company’s lead product, VONJO (pacritinib), is an oral kinase inhibitor approved for treating myelofibrosis patients with severe thrombocytopenia. CTI BioPharma is also advancing several clinical trials, including PACIFICA, PAC203, and PRE-VENT, which explore various applications of pacritinib. The company collaborates with partners like Teva Pharmaceutical Industries and S*BIO Pte Ltd for the production and distribution of its therapies, primarily serving adult patients with myelofibrosis.